NORGINE LAUNCHES NEW DISCUSSION PAPER – SCOPE FOR CHANGE: WHAT NEXT FOR EUROPEAN COLONOSCOPY SERVICES?

Back to media releases
Next media release
25 September 2017

CORPORATE PRESS RELEASE

NORGINE LAUNCHES NEW DISCUSSION PAPER –  SCOPE FOR CHANGE: WHAT NEXT FOR EUROPEAN COLONOSCOPY SERVICES?

 

Amsterdam, The Netherlands, Monday 25 September 2017, 08:00 am CET. Norgine B.V. today announced it has launched a new discussion paper “Scope for change: what next for European colonoscopy services?” which identifies five key areas that pose challenges for colonoscopy service provision, but also offer significant opportunities to enhance patient care. This represents the first major milestone of Scope for change, a programme designed to ignite debate among the European colonoscopy community.  

Included in the discussion paper is a vision for the future, along with a number of commitments that Norgine intends to take forward to ensure it is making the greatest possible contribution it can to healthcare communities in order to improve patients’ experiences of care, and crucially to save lives.

Key areas:

  1. Improving quality: how do we address variations in the quality of services, both within and between European countries?
  2. Expanding access: how can we ensure access to high-quality colonoscopy services in a timely manner and at a location close to home for all patients who need them?
  3. Changing perceptions: how can we improve understanding of the importance of colonoscopy and encourage people to take up the opportunity for screening?
  4. Embracing technology and medical innovation: how do we boost innovation and spread technological advances?
  5. Ensuring funding: how should the community plan and invest to ensure sustainable colonoscopy services for patients today and in the future?

Dr Alastair Benbow, Chief Development and Medical Officer at Norgine said: “This paper is a clear commitment to build on Norgine’s long-established heritage in the area of colonoscopy. It reinforces our continuing work in partnership with the healthcare and patients’ communities, now and in the future.”

He added: “Over the past decades, Norgine’s innovations have significantly advanced patient care by improving bowel cleansing quality – an important factor for detecting adenomas and polyps. We want every patient who needs bowel investigation to have quicker access to a range of innovative diagnostic tools, treatments, and medical technologies, which ultimately prevent diseases at an early stage and save lives.”

Norgine reflected on the insights garnered during a pan-European colonoscopy listening exercise completed earlier this year to produce the discussion paper. This involved interviewing over twenty representatives across Europe from stakeholder groups including healthcare professionals, patient groups, policymakers, budget holders, media and the research community.

 

Notes to Editors:

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

Media Contact:

Isabelle Jouin, T: +44 (0)1895 453643

Follow us @norgine

 

GL/COR/0817/0117d